or on the link below. Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases.
New York, March 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Diffuse Large B-cell Lymphoma (DLBCL) - Competitive Landscape in ...
Tycel J. Phillips, MD, reflects on the challenging case of a patient with double-hit lymphoma, initially treated with R-CHOP before the establishment of preferred options like dose-adjusted EPOCH-R or ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/p7xnl2/diffuse_large) has announced the addition of the "Diffuse Large B ...
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial Diffuse large B-cell ...
Dublin, Dec. 03, 2021 (GLOBE NEWSWIRE) -- The "Diffuse Large B-cell Lymphoma (DLBCL) - Competitive Landscape in 2021" report has been added to ResearchAndMarkets.com's offering. The "Diffuse Large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback